Claire Burton ‘22 pitched Amgen (NASDAQ: AMGN) on April 4th, 2022, which is a biotechnology medicines company that focuses on the treatment and curability of serious illnesses. Amgen was founded in 1980 as Applied Molecular Genetics, shortened its name to Amgen, and went public on the NASDAQ in 1983. The stock is currently a member of the S&P 500 Index, the Fortune 500 and the Dow Jones Industrial Average. Company sales are generated in one business segment, Human Therapeutics, and operations are segmented into inflammation, oncology/hematology and general medicine. The company is headquartered in Thousand Oaks, California, and operates around 180 properties around the world primarily in the US. Amgen has proven to be relatively defensive and resistant to changes in economic cycles given the inelasticity of health care demand and disease treatment to economic conditions. Claire’s investment thesis was focused on Amgen’s innovation, industry domination, ESG focus, and ability to return capital to shareholders. SMIF voted to buy 250 shares of Amgen (AMGN) at market price and fund the position with 500 shares of Morgan Stanley (MS) and 34 shares of SPY.